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73 Abstract Human immunodeficiency virus type-1 (HIV) infection of the central
nervous system promotes neuronal injury and apoptosis that
culminate in HIV-associated neurocognitive disorders (HAND). Viral
proteins, such as transactivator of transcription (Tat), have emerged
as leading candidates to explain HIV-mediated neurotoxicity,
though the mechanism remains unclear. To determine the effects
of Tat, rat cortical neurons were exposed to nanomolar
concentrations of Tat for various time points. Within a few hours,
Tat induced the production of reactive oxygen species (ROS), and
other indices of mitochondrial destabil ization. In addition, we
observed a significant induction of DNA double-strand breaks (DSBs)
by Tat. We next investigated the neuroprotective activity of the
pituitary adenylate cyclase-activating polypeptide 27 (PACAP27)
against these cardinal features of Tat-induced neurodegeneration.
PACAP27 (100 nM) inhibited all Tat-mediated toxic effects
including DNA DSBs. Importantly, PACAP27 prevented the
induction of neuronal loss induced by Tat. The neuroprotective
effect of PACAP27 is correlated with its abil ity to release the
anti-apoptotic chemokine CCL5. Our data support a mechanism of
Tat neurotoxicity in which Tat induces mitochondrial
destabil ization, thus increasing the release of ROS, which causes
DNA DSBs leading to cell death. PACAP27, through CCL5,
mitigates the effects of Tat-induced neuronal dysfunction,
suggesting that PACAP27 could be a new strategy for an adjunct
therapy against HIV-associated neurocognitive disorders.
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13 Abstract Human immunodeficiency virus type-1 (HIV) in-
14 fection of the central nervous system promotes neuronal injury
15 and apoptosis that culminate in HIV-associated
16 neurocognitive disorders (HAND). Viral proteins, such as
17 transactivator of transcription (Tat), have emerged as leading
18 candidates to explain HIV-mediated neurotoxicity, though the
19 mechanism remains unclear. To determine the effects of Tat,
20 rat cortical neurons were exposed to nanomolar concentra-
21 tions of Tat for various time points. Within a few hours, Tat
22 induced the production of reactive oxygen species (ROS), and
23 other indices of mitochondrial destabilization. In addition, we
24 observed a significant induction of DNA double-strand breaks
25 (DSBs) by Tat. We next investigated the neuroprotective
26 activity of the pituitary adenylate cyclase-activating
27polypeptide 27 (PACAP27) against these cardinal features of
28Tat-induced neurodegeneration. PACAP27 (100 nM)
29inhibited all Tat-mediated toxic effects including DNA
30DSBs. Importantly, PACAP27 prevented the induction of
31neuronal loss induced by Tat. The neuroprotective effect of
32PACAP27 is correlated with its ability to release the anti-
33apoptotic chemokine CCL5. Our data support a mechanism
34of Tat neurotoxicity in which Tat induces mitochondrial de-
35stabilization, thus increasing the release of ROS, which causes
36DNA DSBs leading to cell death. PACAP27, through CCL5,
37mitigates the effects of Tat-induced neuronal dysfunction,
38suggesting that PACAP27 could be a new strategy for an
39adjunct therapy against HIV-associated neurocognitive
40disorders.
41Keywords DNAdamage . Oxidative stress . Mitochondria .
42CCL5 . HIV . gp120
43Introduction
44Human immunodeficiency virus type-1 (HIV) causes HIV-
45associated neurocognitive disorders (HAND) in nearly one
46third of individuals (Heaton et al. 2011). Postmortem brains
47from subjects with the most severe form of HAND, HIV-
48associated dementia (HAD), exhibit neuronal loss accompa-
49nied by synaptic simplification, dendritic pruning, loss of
50spines, degradation of synaptic proteins (Crews et al. 2009)
51and neuronal apoptosis (James et al. 1999; Garden et al.
522002). These neurotoxic properties of HIV have been attrib-
53uted to the combined effect of host cell-derived factors, in-
54cluding cytokines and glutamate, and other neurotoxins pro-
55duced by activated microglia/macrophages (Kaul et al. 2001).
56Moreover, different viral proteins have been shown to directly
57cause this type of neuronal degeneration including
58transactivator of transcription (Tat) a 101 amino acid protein
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59 that regulates transcription from the HIV promoter (Chen et al.
60 1997; Haughey et al. 2001; Bruce-Keller et al. 2003). In
61 infected individuals, Tat is actively secreted from infected
62 astrocytes, microglia, and macrophages and can be rapidly
63 internalized by a variety of cell types, including neurons (Liu
64 et al. 2000). This internalization has been reported to promote
65 trimming of neurites, mitochondrial dysfunction, and cell
66 death in neurons (reviewed in Pocernich et al. 2005), all of
67 which correlate with the neurological and cognitive decline
68 more highly than cell death or viral load (Ances and Ellis
69 2007). At present, there are no therapies that target Tat.
70 Tat-induced synaptic loss has been observed to differ both
71 temporally and mechanistically from neuronal cell death (Kim
72 et al. 2008); thus, synapse loss is not necessarily a step on the
73 path to apoptosis. Additionally, Tat-induced synaptic loss has
74 been observed to be reversible in vitro (Kim et al. 2008),
75 suggesting the amelioration of Tat-induced toxicity may be a
76 target for adjunct therapies and the reduction of cognitive
77 deficits. Significant neurological improvement accompanies
78 initiation of highly active antiretroviral therapy in patients
79 with HAD (Bellizzi et al. 2006), consistent with the idea that
80 cognitive impairment is due at least in part to reversible
81 actions of the virus. Determining the specific mechanisms
82 leading to neuronal dysfunction will enable the identification
83 of an effective mechanism for prevention of the
84 neurocognitive decline observed in most cases of HIV. Thus,
85 a protective agent acting upstream of the neurotoxic Tat path-
86 way, before synaptic loss and cell death events are activated, is
87 necessary in order to improve both neuronal survival and
88 connectivity. Previous explorations of compounds to protect
89 against Tat toxicity have failed as viable options in part due to
90 their widespread antagonistic properties (Pocernich et al.
91 2005). Thus, a new compound lacking broad adverse effects
92 is necessary for adjunct therapeutic potential.
93 Pituitary adenylate cyclase-activating peptide (PACAP) is a
94 member of the secretin/glucagon/vasoactive intestinal peptide
95 (VIP) superfamily. PACAP is an endogenous peptide synthe-
96 sized by all tissues in the body including the central nervous
97 system and is expressed in two bioactive isoforms, the pitui-
98 tary adenylate cyclase-activating polypeptides PACAP27 and
99 PACAP38, differing only in amino acid length (reviewed in
100 Vaudry et al. 2009). PACAPs signal through two G protein-
101 coupled receptor subtypes, the low-affinity VPAC receptors
102 (VPAC1 and VPAC2), which they share with VIP, and the
103 high-affinity PACAP-specific receptor, PAC1R (May et al.
104 2010). Binding of the peptide to PAC1R initiates signaling
105 through adenylyl cyclase and cAMP as well as, to a lesser
106 extent, phosphatidylinositol 4,5-bisphosphate. Additionally,
107 PACAP is able to cross the plasma membrane in a receptor-
108 independent manner, initiating signaling in this fashion (Doan
109 et al. 2012). Through these signaling cascades, PACAP sup-
110 ports a number of neuroprotective roles, protecting against
111 excitotoxicity, stabilizing mitochondrial membrane potential,
112and reducing reactive oxygen species (ROS) production
113(Reglodi et al. 2011) and even preventing cortical neuron
114death through anti-inflammatory properties (Sanchez et al.
1152009b). In the present study, we have investigated the protec-
116tive effects of PACAP on Tat-induced neurotoxicity. We dem-
117onstrated that PACAP27 is able to mitigate the toxic effects of
118Tat that are believed to contribute to neuronal loss.
119Materials and Methods
120Reagents
121The preparation of recombinant Tat 1-72 protein has been
122described previously (Ma and Nath 1997). Tat was also pur-
123chased from Immunodiagnostics (Woburn, MA). PACAP27
124and PACAP38were synthesized in the Department ofMedical
125Chemistry, Szeged University, Hungary according to previous
126descriptions (Jozsa et al. 2005) or were purchased from R&D
127(Minneapolis, MN).
128Cell Cultures
129Cortical neuronal cultures were prepared from the cortex of
130embryonic (E17–18) Sprague–Dawley rats (Charles River,
131Gaithersburg, MD) following an established protocol
132(Avdoshina et al. 2010). Cells were seeded onto poly-L-lysine
133precoated plates in neurobasal medium (NBM) containing
1342 % B27 supplement, 25 nM glutamate, 0.5 mML-glutamine,
135and 1 % antibiotic–antimycotic solution (Invitrogen,
136Carlsbad, CA). Cultures were grown at 37 °C in 5 % CO2/
13795 % air for 7–8 days. Cultures contained ~10 % of non-
138neuronal cells.
139Astrocytes were prepared from the cerebral cortex of 1- to
1402-day-old Sprague–Dawley rats according to an established
141protocol (Avdoshina et al. 2010). Cells were seeded on poly-L-
142lysine precoated tissue culture flasks in Dulbecco’s modified
143eagle medium (DMEM, Invitrogen) containing 10 % fetal
144bovine serum, 2 % antibiotic–antimycotic and grown at
14537 °C in 5 % CO2/95 % relative atmosphere.
146Cells were exposed to control medium (heat-inactivated
147Tat in 0.1 % bovine serum albumin, BSA), 10, 100, or
1481,000 nM Tat (in 0.1 % BSA) and 100 nM PACAPs (in
1490.1 % BSA) for various time points.
150ROS Levels
151Intracellular accumulation of ROS was determined with
152H2DCF-DA (Sigma-Aldrich, St. Louis, MO). This nonfluo-
153rescent compound accumulates within cells upon
154deacetylation. H2DCF then reacts with ROS to form fluores-
155cent dichlorofluorescein (DCF). Following exposure to Tat
156and other compounds for 15 min alone or in combination,
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157 cells were loaded with H2DCF-DA (5 μg/ml) at 37 °C for
158 45 min in a humidified 5 % CO2/95 % air incubator. The free
159 dye was washed away by several medium changes and fluo-
160 rescence was measured with an excitation wavelength of
161 488 nm and emission wavelength of 525 nm (Synergy H4
162 hybrid reader, Biotek, Winooski, VT).
163 MTTAssay
164 The activity of mitochondrial dehydrogenases [3(4,5-dimeth-
165 ylthiazol-2-yl)-2.5-diphenyltetrazolium bromide] (MTT as-
166 say) was used to determine mitochondria viability. This assay
167 was carried out according to the manufacturer's specifications
168 (MTT Cell Grow Assay Kit, Millipore, Temecula, CA) as
169 described previously (Bachis et al. 2003; Avdoshina et al.
170 2010).
171 Neutral Comet Assay
172 The CometAssay® kit (Trevigen, Gaithersburg, MD) was
173 used with some modifications. Cells in 12-well plates were
174 rinsed with ice-cold phosphate-buffered saline (PBS, Ca2+/
175 Mg2+-free), gently scraped and transferred to a centrifuge tube
176 where they were pelleted. Pellets were then washed in ice-cold
177 PBS and cells were resuspended at 1×105 cells/ml in ice-cold
178 PBS. Cells were combined with molten low melting-point
179 agarose at 37 °C (LMAgarose, Trevigen) at a ratio of 1:10
180 (v/v), and 50 μl of the cells/LMAgarose mixture was spread
181 onto CometSlides (Trevigen). After cooling at 4 °C for 10 min
182 to allow LMAgarose to solidify, slides were placed in lysis
183 buffer overnight. Following lysis, slides were washed with 1×
184 TBE buffer (CellgroMediatech, Manassas, VA) and subjected
185 to electrophoresis in TBE buffer. Electrophoresis was con-
186 ducted at 1 V/cm for 30 min at 4 °C. The slides were washed
187 twice with ddH2O for 10min and dehydrated with 70% EtOH
188 (Sigma-Aldrich) for 5 min. Slides were placed in a dry oven at
189 45 °C until dry (~15 min). Subsequently, cells were stained
190 with SYBR Green (Trevigen) for 10 min, air-dried and stored
191 in the dark with desiccating material until imaging. Images
192 taken with Nikon eclipse Ni microscope were analyzed using
193 ImageJ (National Institutes of Health, Bethesda, MD). Tail
194 moment, the length from the center of the head of the comet to
195 the end of the tail, was quantified as a measure of DNA
196 double-strand breaks (DSBs).
197 Hoechst 33258/Propidium Iodide
198 The viability of primary cortical neurons was estimated by
199 Hoechst 33258 and propidium iodide (Hoechst/PI; Sigma-
200 Aldrich) co-staining and visualized using a fluorescence mi-
201 croscope. Briefly, cultures were incubated simultaneously
202 with Hoechst 33258 and PI (both 5 μg/ml) for 30 min at
203 37 °C. Neurons were imaged in four microscopic fields in
204each well (three wells/treatment). Reaction was visualized
205with an Olympus IX71 (Tokyo, Japan) inverted fluorescence
206microscope. Hoechst/PI-positive cells were then counted
207using ImageJ and expressed as a percentage of the total
208number of neurons.
209Enzyme-Linked Immunosorbent Assay
210Levels of CCL5 were determined in the culture medium using
211the DuoSet enzyme-linked immunosorbent assay (ELISA)
212Development System Kits (R&D, Minneapolis, MN), accord-
213ing to the manufacturer’s instructions and as described previ-
214ously (Avdoshina et al. 2010).
215Statistical Analysis
216Statistical analysis was performed using ANOVA and
217Bonferroni’s test for multiple comparisons (GraphPad Prism
2185, La Jolla, CA).
219Results
220PACAP27 Prevents Tat-Induced Mitochondrial
221Destabilization
222The neurotoxic effect of Tat and the potential neuroprotection
223of PACAP were first analyzed by the MTT colorimetric assay
224in rat cortical neurons. As shown in Fig. 1, Tat (100 nM)
225significantly decreased MTT when compared to control (me-
226dium containing heat-inactivated Tat in 0.1 % BSA), suggest-
227ing that Tat promotes mitochondrial damage. The neurotoxic
228effect of Tat was not seen using a lower concentration
Fig. 1 Tat-induced mitochondrial impairment is attenuated by
PACAP27. Neurons were exposed to control medium (heat-inactivated
Tat in 0.1 % BSA) or medium containing Tat (100 nM), PACAP27
(100 nM) or PACAP38 (100 nM) alone or in combination. Cell viability
was determined 24 h later by MTT assay. Data, expressed as arbitrary
units (A.U.) are the mean±SEM of three independent experiments (n=
24). *p<0.01 vs. control; #p<0.05 vs. control
J Mol Neurosci
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229 (10 nM), whereas a higher concentration (1 μM) elicited a
230 quantitative effect similar to that obtained with 100 nM con-
231 centration (data not shown). Both PACAP38 (100 nM) and
232 PACAP27 (100 nM) alone did not significantly change MTT
233 (Fig. 1). However, PACAP27 pretreatment was able to pre-
234 vent Tat toxicity (Fig. 1). PACAP38 was significantly less
235 potent than PACAP27 (Fig. 1). Therefore, for the continuation
236 of this study, we used PACAP27.
237 Mitochondrial damage leads to the increased production
238 and release of reactive oxygen species (ROS) into the cyto-
239 plasm and extracellular space. To further assess the toxic
240 effects of Tat and the neuroprotective effect of PACAP27,
241 we quantified ROS accumulation in neuronal cultures.
242 Congruent with the results observed in the mitochondrial
243 viability assay, ROS levels were significantly increased in
244 neurons following a 15-min exposure to Tat (Fig. 2).
245 PACAP27 pretreatment attenuated this increase in ROS accu-
246 mulation (Fig. 2), confirming the ability of this neuropeptide
247 to prevent mitochondrial destabilization.
248 Tat, PACAP27, and DNA Damage
249 The overproduction of free radicals can induce oxidation of
250 DNA bases, and consequently, DNA damage including DNA
251 double-strand breaks (DSBs), the most severe type of DNA
252 damage. If not repaired properly, DSB damage can lead to
253 long-term neuronal injury. DSBs can be quantified using
254 single-cell gel electrophoresis (Neutral Comet Assay).
255 Neurons exposed to Tat for varying time points exhibited a
256 greater number of DNA fragments migrating out of the nuclei
257 to form the “comet tail” than control (heat-inactivated Tat in
258 0.1%BSA) neurons, indicating a significantly greater number
259 of DNA DSBs (data not shown). This effect was seen as early
260 as 15 min after Tat exposure (Fig. 3). PACAP27 prevented
261 Tat-induced DNA DSBs. In fact, cultures exposed to
262 PACAP27 15 min prior to Tat exhibited significantly less
263DNA DSBs than Tat alone (Fig. 3), suggesting that
264PACAP27 may either prevent DNA DSB damage or facilitate
265the DSB repair process.
266Astrocytes are more resistant than neurons to Tat-induced
267toxicity (Pocernich et al. 2004; Eugenin et al. 2007). To
268determine whether DNA DSBs underlie Tat neurotoxicity,
269we assessed DNA DSBs in cultured astrocytes following
270exposure to Tat. This viral protein did not cause a significant
271change in DNA DSBs in astrocytes (Fig. 4), indicating that
272this mechanism of Tat-induced damage may be neuron-
273specific.
274PACAP27 Inhibits Tat-Induced Neuronal Cell Death
275Mitochondrial health and DNA damage are acceptable prox-
276ies for neuronal health and viability; nevertheless, our data so
277far has failed to demonstrate the causal relationship between
278mitochondrial alteration and neuronal death. Thus, we
279assessed cell death at time points beyond the observed mito-
280chondrial impairment and DNA DSB accumulation by using
281Hoechst/PI. Neurons were exposed to Tat for several time
282points up to 72 h. Control cells were exposed to heat-
283inactivated Tat in 0.1 % BSA for the same time points.
284While cell death was not significantly different from control
285at 24 and 48 h after Tat exposure, there was a significant
286increase in cell death 72 h after exposure (Fig. 5). Cultures
287exposed to PACAP27 before Tat had a similar proportion of
288cell death, as compared to those treated with PACAP27 alone
289and untreated controls (Fig. 5), indicating PACAP27 is effec-
290tive in protecting neurons from Tat-induced death.
291Potential Mechanisms of Neuroprotection
292PACAP has been shown to activate a number of neuroprotec-
293tive pathways (Reglodi et al. 2011). Relevant for Tat toxicity
294is the fact that PACAP38 and related neuropeptide VIP can
295also induce the release of CCL5 from astrocytes (Brenneman
296et al. 2002). Released CCL5, in turn, is neuroprotective
297against neurotoxins (Sanchez et al. 2009a) including the
298HIV viral protein gp120 (Brenneman et al. 1988; Avdoshina
299et al. 2010). Therefore, we tested whether PACAP27 releases
300CCL5 in our neuronal cultures. We observed that PACAP27
301promotes the release of CCL5 from our cultures that contain
302~10 % of astrocytes (data not shown). However, the effect of
303PACAP on CCL5 release was significantly more robust in
304primary cultures of astrocytes (Fig. 6). Thus, we confirm
305previous data that PACAP enhances the release of CCL5
306mainly from astrocytes (Brenneman et al. 2002).
307To establish whether CCL5 prevents Tat toxicity in our
308experimental system, cultures were then exposed to CCL5
309(20 nM) 15 min prior to Tat. MTT assay revealed that CCL5
310inhibits the mitochondrial impairment induced by Tat (Fig. 7).
Fig. 2 Tat-induced ROS release is attenuated by PACAP27. Cortical
neurons were exposed to control medium, Tat (100 nM) or PACAP27
(100 nM) alone or in combination for 15 min. ROS production was
determined by H2DCF-dA fluorescence as described in “Materials and
Methods” section. Data, expressed as percent of control, are the mean±
SEM from three independent experiments (n=2 each experiment).
#p<0.05 vs. control
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311 Thus, it appears that CCL5 prevents the toxic effect of not
312 only gp120 but also Tat.
313 Discussion
314 The ability of Tat to induce neuronal damage and dysfunction
315 in vitro and in vivo has been established (reviewed in Li et al.
316 2009). Several mechanisms have been suggested to underlie
317 the neurotoxic effect of Tat. These include activation of
318 NMDA receptors (Haughey et al. 2001; Eugenin et al. 2007;
319Li et al. 2008), impairment of mitochondria physiology (Chen
320et al. 2002; Norman et al. 2007), and production of reactive
321oxygen species (Kruman et al. 1998) which ultimately may
322result in apoptosis. Our study showed that Tat, in addition to
323the destabilization of mitochondria and production of ROS
324previously described ( Q2Hui et al. 2012), promotes accumulation
325of DNA DSBs, which can be lethal to cells. These events start
326as early as 15 min after Tat exposure and they occur at least a
327couple of days before neuronal cell death. Additionally, Tat
328caused a significant increase in the number of DNA DSBs in
329neurons, but not astrocytes, which are “resistant” to the toxic
Fig. 3 PACAP27 pretreatment protects against Tat-induced DNA DSBs
in neurons. a Representative images of neurons exposed to control
medium (heat-inactivated Tat in 0.1 % BSA), Tat (100 nM), PACAP27
(100 nM) alone or in combination for 15min showing tail moment. Insets
are enlargements to show “tails.” b Quantification of tail moment
representing DNA DSBs. Data, expressed as arbitrary units, are the mean
of 100 cells/treatment randomly selected from four fields. The experiment
was repeated four times. *p<0.01 vs. control
Fig. 4 Tat does not induce DNA DSBs in astrocytes. Cortical astrocytes
were prepared as described in “Materials and Methods” section. a Represen-
tative images of astrocytes exposed to Tat (100 nM), PACAP27 (100 nM)
alone or in combination for 15 min showing tail moment. Tail moment was
quantified as described in “Materials and Methods” section. Insets are en-
largements to show “tails.” b Quantification of tail moment representing
DNA DSBs. Data, expressed as arbitrary units, are the mean±SEM of
100 cells/treatment from four fields (from two independent experiments)
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330 effect of Tat. Importantly, all of these neurotoxic effects of Tat
331 were lessened by a 15-min pretreatment with PACAP27.
332 Tat induces ROS production, rapid loss of mitochondrial
333 membrane potential and increases mitochondrial uptake of
334 intracellular calcium (Mattson et al. 2005). Tat injections into
335 the frontal cortex of young adult mice lead to irregularly
336 shaped and enlarged mitochondria (Norman et al. 2008).
337 This aberrant morphology mirrors the mitochondrial irregu-
338 larities observed in the cortex of patients with HIV encepha-
339 litis (Zhang et al. 2012), indicating the relevance of mitochon-
340 drial impairment to disease progression. Mitochondria are
341 vital for cell function, wherein they supply up to 95 % of the
342 required ATP and regulate intracellular calcium homeostasis.
343 In neurons, mitochondria must travel extreme distances (e.g.,
344 axons) and maintain energy homeostasis in these highly met-
345 abolically active cells. In fact, synaptic activity and
346mitochondrial motility are highly positively correlated pro-
347cesses (Sun et al. 2013). Neuronal mitochondria are distribut-
348ed to regions of high metabolic demand, including synapses,
349nodes of Ranvier, and myelination/demyelination interfaces.
350Thus, mitochondrial health is intimately tied with the func-
351tional status of neurons. Recently impairments to mitochon-
352drial dynamics have been implicated in a causal role of neu-
353rodegenerative diseases including Parkinson’s, Alzheimer’s,
354and Huntington’s diseases (Eckmann et al. 2013; Itoh et al.
3552013). The prevalence of neuronal diseases associated with
356general mitochondrial impairment underscores the important
357functional relationship between neurons and mitochondria.
358In this study, we observed a significant increase in ROS
359production in neurons exposed to Tat concomitantly to DNA
360DSBs. ROS can interact with a variety of cellular macromol-
361ecules, resulting in oxidative DNA damage, among other ill
Fig. 5 TatQ1 -induced cell death is prevented by PACAP27. Neurons were
exposed to control medium or Tat (100 nM) for the indicated time points.
PACAP27 (100 nM) was added 15min prior to Tat. Quantification of cell
death was done using Hoechst and PI, as described in “Materials and
Methods” section. Data are the mean±SEM from a total of 500 neurons
from 12 randomly selected fields/treatment from two independent exper-
iments. *p<0.01 vs. control
Fig. 6 PACAP27 induces the release of CCL5 from astrocytes. Rat
primary astrocytes were exposed to control medium, or medium contain-
ing PACAP27 (100 nM) for 15 min and 24 h. The medium was collected
and an aliquot was used to determine CCL5 levels by ELISA. CCL5
levels in control cells at 24 h were 104±5 picograms per milliliter). Data
are the mean±SEM of three independent samples at each time point.
*p<0.05 vs. control
Fig. 7 CCL5 prevents Tat-induced mitochondrial destabilization. Corti-
cal cultures were exposed to control medium, Tat alone or in combination
with CCL5 (20 nM). CCL5 was added 15 min prior to Tat. Cell viability
was determined 24 h after Tat exposure byMTTassay. Data, expressed as
percent of control, are the mean±SEM of four independent samples.
*p<0.05 vs. control
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362 effects. As postmitotic cells, neurons are particularly vulnera-
363 ble to DNA DSBs. However, DNA damage even within
364 neurons does not immediately induce apoptosis. The accumu-
365 lation of DNA damage that is not repaired or is incorrectly
366 repaired will lead to errors in protein translation, resulting in
367 misfolded proteins and eventual cellular dysfunction and cell
368 death (Brasnjevic et al. 2008; Jeppesen et al. 2011). The
369 precise load of DNA damage any neuron can withstand re-
370 mains unclear. Nevertheless, DNA damage has increasingly
371 been observed in neurodegenerative diseases (Fishel et al.
372 2007) including HAND, where a significant accumulation of
373 DNA damage has been observed in the post-mortem brain
374 tissue of HIV patients with cognitive deficits (Zhang et al.
375 2012). Indeed, patients with HAND had an average of 45% 8-
376 oxoG positive cells, compared to only 30 % in HIV patients
377 without HAND and 4% in controls (Zhang et al. 2012). These
378 results suggest that nuclear DNA damage exists at least in part
379 due to the high levels of ROS, likely contributing to neuronal
380 injury and cell death. The present study is the first implicating
381 Tat in the development of DNA damage in neurons, preceding
382 cell death.
383 Both PACAPs protect neurons from diverse insults such as
384 excitotoxicity, oxidative stress, and ischemia (Vaudry et al.
385 2002; Ohtaki et al. 2010). Most of these injuries result in the
386 production of ROS; though it is not clear how PACAPs
387 regulate this oxidative stress. Some reports have raised the
388 possibility of PACAPs’ involvement in the production of
389 antioxidants (Fabian et al. 2012). Our findings demonstrate
390 for the first time that PACAP27 prevents Tat-induced neuro-
391 toxicity. The neuroprotective activity of PACAP27 on viral
392 proteins is not surprising because previous studies have shown
393 that both PACAP27 and PACAP38 attenuate neuronal death
394 induced by the HIVenvelope protein gp120 (Brenneman et al.
395 2002). Surprisingly, PACAP38 was unable to counteract the
396 toxic effect of Tat. This appears to be a contradictory result
397 because both PACAPs bind to same receptors and share a
398 similar pharmacological profile. On the other hand, previous
399 studies have shown that PACAP38 and PACAP27 have an
400 opposite profile on the secretion of luteinizing hormone, most
401 likely through a vasoactive intestinal peptide receptor, VPAC1
402 (Kantora et al. 2000). Thus, different receptors may mediate
403 the neuroprotective effect against Tat. On the other hand,
404 PACAPs can also be neuroprotective by the activation of
405 anti-apoptotic chemokines such as CCL5. CCL5 exerts neu-
406 roprotective activity against other viral proteins such as gp120
407 (Kaul et al. 2007; Avdoshina et al. 2010). Indeed, both
408 PACAP38 (Brenneman et al. 2002) and PACAP27 promote
409 the release of CCL5 from astrocytes. Intriguingly, Brenneman
410 et al. (2002) have shown that the ability of PACAP38 to
411 induce the release of CCL5 from astrocytes is biphasic and
412 concentration-dependent, with the maximal activity on the
413 release of CCL5 in the low picomolar range. Thus, we may
414 have used a concentration of PACAP38 that does not release
415sufficient amount of CCL5 to prevent Tat toxicity. Further
416studies are needed to confirm this hypothesis. Hence, while
417we cannot point at a specific mechanism of PACAP27 neuro-
418protection we cannot exclude the hypothesis that PACAP27
419may be neuroprotective against Tat because of its antioxidant
420property combined with its ability to release CCL5. Future
421studies, using CCL5 knock-out animals or a CCL5 blocking
422antibody, will prove or disprove this hypothesis.
423Whereas CCL5 is one mechanism by which PACAP27 can
424be neuroprotective, other mechanisms may also be implicated
425including the activation of cAMP-protein kinase A pathway
426which then activates cAMP-response element binding
427protein-mediated gene expression (Baxter et al. 2011).
428PACAPs have also been previously observed to provide
429neurotrophin-like protection to different populations of neu-
430rons (Reglodi et al. 2011). For instance, PACAP exhibits
431properties similar to nerve growth factor (NGF) in peripheral
432neurons (Lioudyno et al. 1998), and both PACAP forms
433activate TrkA and TrkB, the tyrosine kinase receptors for
434NGF and brain-derived neurotrophic factor (BDNF), respec-
435tively (Lee et al. 2002). TrkA is mostly localized in the basal
436forebrain; thus, TrkA most likely does not account for the
437neuroprotective effect of PACAP against Tat. Nevertheless,
438activation of TrkB could participate in fast-acting protection
439that we have observed in vitro. Indeed, BDNF is particularly
440potent as neuroprotective compound against Tat (Ramirez
441et al. 2001) and gp120 (Bachis et al. 2003). This would be
442in line with a recent study (Nath et al. 2012) showing that
443flavonoids, alkaloids present in many plants, prevent Tat-
444mediated mitochondrial dysfunction and neuritic damage by
445up-regulating the expression of BDNF. Thus, the ability of
446PACAP to activate TrkB signaling pathways could provide an
447additional neurotrophic effect against Tat. Our results do not
448exclude that CCL5 works in concert with BDNF or other
449trophic factors. In conclusion, our findings implicate
450PACAP27 as a potent neuroprotective peptide against Tat;
451however, more experiments are needed to further examine
452mechanisms underlying its neuroprotective effect. Such
453mechanisms may yield novel targets for preventing Tat-
454mediated neuronal injury and delay HAND.
455Acknowledgments This work was partly supported in part by HHS
456grant T32 NS041218 to SR and NS079172 and NS074916 to IM.
457PACAP synthesis was supported by OTKAK104984 NAP,
458TAMOP4.2.2.A-11/1/KONV-2012-0024, Arimura Foundation, PTE-
459MTA “Lendület” Program.
460References 461
462Ances BM, Ellis RJ (2007) Dementia and neurocognitive disorders due to
463HIV-1 infection. Semin Neurol 27:86–92
464Avdoshina V, Biggio F, Palchik G, Campbell LA, Mocchetti I (2010)
465Morphine induces the release of CCL5 from astrocytes: potential
J Mol Neurosci
JrnlID 12031_ArtID 273_Proof# 1 - 03/03/2014
AUTHOR'S PROOF
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
466 neuroprotective mechanism against the HIV protein gp120. Glia 58:
467 1630–1639
468 Bachis A, Major EO, Mocchetti I (2003) Brain-derived neurotrophic
469 factor inhibits human immunodeficiency virus-1/gp120-mediated
470 cerebellar granule cell death by preventing gp120 internalization. J
471 Neurosci 23:5715–5722
472 Baxter PS, Martel M-A, McMahon A, Kind PC, Hardingham GE (2011)
473 Pituitary adenylate cyclase-activating peptide induces long-lasting
474 neuroprotection through the induction of activity-dependent signal-
475 ing via the cyclic AMP response element-binding protein-regulated
476 transcription co-activator 1. J Neurochem 118:365–378
477 BellizziMJ, Lu SM,Gelbard HA (2006) Protecting the synapse: evidence
478 for a rational strategy to treat HIV-1 associated neurologic disease. J
479 Neuroimmune Pharm 1:20–31
480 Brasnjevic I, Hof PR, Steinbusch HW, Schmitz C (2008) Accumulation
481 of nuclear DNA damage or neuron loss: molecular basis for a new
482 approach to understanding selective neuronal vulnerability in neu-
483 rodegenerative diseases. DNA Repair (Amst) 7:1087–1097
484 Brenneman DE, Westbrook GL, Fitzgerald SP et al (1988) Neuronal cell
485 killing by the envelope protein of HIV and its prevention by vaso-
486 active intestinal peptide. Nature 335:639–642
487 Brenneman DE, Hauser JM, Spong C, Phillips TM (2002) Chemokine
488 release is associated with the protective action of PACAP-38 against
489 HIVenvelope protein neurotoxicity. Neuropeptides 36:271–280
490 Bruce-Keller AJ, Chauhan A, Dimayuga FO, Gee J, Keller JN, Nath A
491 (2003) Synaptic transport of human immunodeficiency virus-Tat
492 protein causes neurotoxicity and gliosis in rat brain. J Neurosci 23:
493 8417–8422
494 Chen P, Mayne M, Power C, Nath A (1997) The Tat protein of HIV-1
495 induces tumor necrosis factor-alpha production. Implications for HIV-
496 1-associated neurological diseases. J Biol Chem 272:22385–22388
497 Chen D,WangM, Zhou S, ZhouQ (2002) HIV-1 Tat targets microtubules
498 to induce apoptosis, a process promoted by the pro-apoptotic Bcl-2
499 relative Bim. EMBO J 21:6801–6810
500 Crews L, Patrick C, Achim CL, Everall IP, Masliah E (2009) Molecular
501 pathology of neuro-AIDS (CNS-HIV). Int J Mol Sci 10:1045–1063
502 Doan ND, Chatenet D, Letourneau M, Vaudry H, Vaudry D, Fournier A
503 (2012) Receptor-independent cellular uptake of pituitary adenylate
504 cyclase-activating polypeptide. BiochimBiophys Acta 1823:940–949
505 Eckmann J, Eckert SH, Leuner K, Muller WE, Eckert GP (2013)
506 Mitochondria: mitochondrial membranes in brain ageing and neu-
507 rodegeneration. Int J Biochem Cell Biol 45:76–80
508 Eugenin EA, King JE, Nath A et al (2007) HIV-tat induces formation of
509 an LRP-PSD-95-NMDAR-nNOS complex that promotes apoptosis
510 in neurons and astrocytes. Proc Natl Acad Sci U S A 104:3438–
511 3443
512 Fabian E, Reglodi D, Mester L et al (2012) Effects of PACAP on
513 intracellular signaling pathways in human retinal pigment epithelial
514 cells exposed to oxidative stress. J Mol Neurosci 48:493–500
515 Fishel ML, Vasko MR, Kelley MR (2007) DNA repair in neurons: so if
516 they don’t divide what’s to repair? Mutat Res 614:24–36
517 Garden GA, Budd SL, Tsai E et al (2002) Caspase cascades in human
518 immunodeficiency virus-associated neurodegeneration. J Neurosci
519 22:4015–4024
520 Haughey NJ, Nath A, Mattson MP, Slevin JT, Geiger JD (2001) HIV-1
521 Tat through phosphorylation of NMDA receptors potentiates gluta-
522 mate excitotoxicity. J Neurochem 78:457–467
523 Heaton RK, Franklin DR, Ellis RJ et al (2011) HIV-associated
524 neurocognitive disorders before and during the era of combination
525 antiretroviral therapy: differences in rates, nature, and predictors. J
526 Neurovirol 17:3–16
527 Itoh K, Nakamura K, Iijima M, Sesaki H (2013) Mitochondrial dynamics
528 in neurodegeneration. Trends Cell Biol 23:64–71
529 James HJ, Sharer LR, Zhang Q et al (1999) Expression of caspase-3 in
530 brains from paediatric patients with HIV-1 encephalitis. Neuropathol
531 Appl Neurobiol 25:380–386
532Jeppesen DK, Bohr VA, Stevnsner T (2011) DNA repair deficiency in
533neurodegeneration. Prog Neurobiol 94:166–200
534Jozsa R, Hollosy T, Tamas A, Toth G, Lengvari I, Reglodi D (2005)
535Pituitary adenylate cyclase activating polypeptide plays a role in
536olfactory memory formation in chicken. Peptides 26:2344–2350
537Kantora O, Molnar J, Arimura A, Koves K (2000) PACAP38 and
538PACAP27 administered intracerebroventricularly have an opposite
539effect on LH secretion. Peptides 21:817–820
540Kaul M, Garden GA, Lipton SA (2001) Pathways to neuronal injury and
541apoptosis in HIV-associated dementia. Nature 410:988–994
542Kaul M, Ma Q, Medders KE, Desai MK, Lipton SA (2007) HIV-1
543coreceptors CCR5 and CXCR4 both mediate neuronal cell death
544but CCR5 paradoxically can also contribute to protection. Cell
545Death Differ 14:296–305
546Kim HJ, Martemyanov KA, Thayer SA (2008) Human immunodeficien-
547cy virus protein Tat induces synapse loss via a reversible process that
548is distinct from cell death. J Neurosci 28:12604–12613
549Kruman II, Nath A, Mattson MP (1998) HIV-1 protein Tat induces
550apoptosis of hippocampal neurons by a mechanism involving cas-
551pase activation, calcium overload, and oxidative stress. Exp Neurol
552154:276–288
553Lee FS, Rajagopal R, Kim AH, Chang PC, Chao MV (2002) Activation
554of Trk neurotrophin receptor signaling by pituitary adenylate
555cyclase-activating polypeptides. J Biol Chem 277:9096–9102
556Li W, Huang Y, Reid R et al (2008) NMDA receptor activation by HIV-
557Tat protein is clade dependent. J Neurosci 28:12190–12198
558Li W, Li G, Steiner J, Nath A (2009) Role of Tat protein in HIV
559neuropathogenesis. Neurotox Res 16:205–220
560Lioudyno M, Skoglösa Y, Takei N, Lindholm D (1998) Pituitary adenyl-
561ate cyclase-activating polypeptide (PACAP) protects dorsal root
562ganglion neurons from death and induces calcitonin gene-related
563peptide (CGRP) immunoreactivity in vitro. J Neurosci Res 51:243–
564256
565Liu Y, Jones M, Hingtgen CM et al (2000) Uptake of HIV-1 tat protein
566mediated by low-density lipoprotein receptor-related protein dis-
567rupts the neuronal metabolic balance of the receptor ligands. Nat
568Med 6:1380–1387
569Ma M, Nath A (1997) Molecular determinants for cellular uptake of Tat
570protein of human immunodeficiency virus type 1 in brain cells. J
571Virol 71:2495–2499
572Mattson MP, Haughey NJ, Nath A (2005) Cell death in HIV dementia.
573Cell Death Differ 12(Suppl 1):893–904
574May V, Lutz E, MacKenzie C, Schutz KC, Dozark K, Braas KM (2010)
575Pituitary adenylate cyclase-activating polypeptide (PACAP)/
576PAC1HOP1 receptor activation coordinates multiple neurotrophic
577signaling pathways: Akt activation through phosphatidylinositol 3-
578kinase gamma and vesicle endocytosis for neuronal survival. J Biol
579Chem 285:9749–9761
580Nath S, Bachani M, Harshavardhana D, Steiner JP (2012) Catechins
581protect neurons against mitochondrial toxins and HIV proteins via
582activation of the BDNF pathway. J Neurovirol 18:445–455
583Norman JP, Perry SW, Kasischke KA, Volsky DJ, Gelbard HA (2007)
584HIV-1 trans activator of transcription protein elicits mitochondrial
585hyperpolarization and respiratory deficit, with dysregulation of com-
586plex IV and nicotinamide adenine dinucleotide homeostasis in cor-
587tical neurons. J Immunol 178:869–876
588Norman JP, Perry SW, Reynolds HM et al (2008) HIV-1 Tat activates
589neuronal ryanodine receptors with rapid induction of the unfolded
590protein response and mitochondrial hyperpolarization. PLoS One 3:
591e3731
592Ohtaki H, Satoh A, Nakamachi T et al (2010) Regulation of oxidative
593stress by pituitary adenylate cyclase-activating polypeptide (PACAP)
594mediated by PACAP receptor. J Mol Neurosci 42:397–403
595Pocernich CB, Sultana R, Hone E et al (2004) Effects of apolipoprotein E
596on the human immunodeficiency virus protein Tat in neuronal
597cultures and synaptosomes. J Neurosci Res 77:532–539
J Mol Neurosci
JrnlID 12031_ArtID 273_Proof# 1 - 03/03/2014
AUTHOR'S PROOF
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
598 Pocernich CB, Sultana R, Mohmmad-Abdul H, Nath A,
599 Butterfield DA (2005) HIV-dementia, Tat-induced oxidative
600 stress, and antioxidant therapeutic considerations. Brain Res
601 Brain Res Rev 50:14–26
602 Ramirez SH, Sanchez JF, Dimitri CA, Gelbard HA, Dewhurst S,
603 Maggirwar SB (2001) Neurotrophins prevent HIV Tat-
604 induced neuronal apoptosis via a nuclear factor-kappaB
605 (NF-kappaB)-dependent mechanism. J Neurochem 78:874–
606 889
607 Reglodi D, Kiss P, Lubics A, Tamas A (2011) Review on the protective
608 effects of PACAP in models of neurodegenerative diseases in vitro
609 and in vivo. Curr Pharm Des 17:962–972
610 Sanchez A, Tripathy D, Grammas P (2009a) RANTES release contrib-
611 utes to the protective action of PACAP38 against sodium nitroprus-
612 side in cortical neurons. Neuropeptides 43:315–320
613Sanchez A, Rao HV, Grammas P (2009b) PACAP38 protects rat cortical
614neurons against the neurotoxicity evoked by sodium nitroprusside
615and thrombin. Regul Pept 152:33–40
616Sun T, Qiao H, Pan PY, Chen Y, Sheng ZH (2013) Motile axonal
617mitochondria contribute to the variability of presynaptic strength.
618Cell Rep 4:413–419
619Vaudry D, Pamantung TF, Basille M et al (2002) PACAP protects
620cerebellar granule neurons against oxidative stress-induced apopto-
621sis. Eur J Neurosci 15:1451–1460
622Vaudry D, Falluel-Morel A, Bourgault S et al (2009) Pituitary adenylate
623cyclase-activating polypeptide and its receptors: 20 years after the
624discovery. Pharmacol Rev 61:283–357
625Zhang Y, Wang M, Li H et al (2012) Accumulation of nuclear and
626mitochondrial DNA damage in the frontal cortex cells of patients
627with HIV-associated neurocognitive disorders. Brain Res 1458:1–11
628
J Mol Neurosci
JrnlID 12031_ArtID 273_Proof# 1 - 03/03/2014
AUTHOR'S PROOF
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
AUTHOR QUERIES
AUTHOR PLEASE ANSWER ALL QUERIES.
Q1. Kindly define images A, B, and C of Fig. 5 at caption.
Q2. “Hui et al. 2012” is cited in text but not given in the reference list. Please provide details in the list
or delete the citation from the text.
